HC Wainwright & Co. maintains Buy rating on Unicycive Therapeutics, $13 price target

HC Wainwright & Co. maintained their Buy rating on Unicycive Therapeutics's stock with a price target of $13.00.The price target implies an upside of 180.2% from the Sep 28 close of $4.64.Key takeaways from the analyst noteStrong Product Pipeline: Unicycive Therapeutics is advancing two promising p…